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A recent study MacLeod et al. has shown that an interaction between variants at the LRRK2 and PARK16
loci inﬂuences risk of development of Parkinson’s disease (PD). Our study examines the proposed
interaction between LRRK2 and PARK16 variants in modifying PD risk using a large multicenter series of
PD patients (7715) and controls (8261) from sites participating in the Genetic Epidemiology of Parkin-
son’s Disease Consortium. Our data does not support a strong direct interaction between LRRK2 and
PARK16 variants; however, given the role of retromer and lysosomal pathways in PD, further studies are
warranted.
 2016 Elsevier Inc. All rights reserved.1. Introduction
Genetic discoveries made over the years either by using linkage,
array, and/or exome-based approaches have helped in advancing
our knowledge of the genetic underpinnings of Parkinson’s disease
(PD) (International Parkinson Disease Genomics Consortium et al.,
2011; Lesage and Brice, 2009; Trinh and Farrer, 2013). As we
discover new loci relevant to idiopathic PD pathogenesis, it has
become imperative to also understand the geneegene interaction
effect in modulating PD risk in population (see Supplementary
Information) (Elbaz et al., 2011). Although the results of most
geneegene interactions studies in PD to date have pointed toward
independent effects for PD susceptibility variants, an exception to
this has been an assessment of functional-genetic interaction
between the LRRK2 and PARK16 loci in which overexpression of
RAB7L1, a candidate gene for PARK16 locus, reversed the effects of
the LRRK2 mutation and rescued the phenotypes (MacLeod et al.,
2013). Therefore, this study aims to evaluate the interaction be-
tween several different LRRK2 and PARK16 variants in determining
PD risk using a Caucasian series with more than 10,000 subjects
from 14 different centers, and an Asian series with more than 5000
subjects from 5 different centers.2. Methods
The Genetic Epidemiology of Parkinson’s Disease (GEoPD) con-
sortium includes investigators from 59 sites, across 30 countries
and 6 continents, as of 2016. A total of 19 sites representing 17
countries and 4 continents agreed to contribute DNA samples and
clinical data for the present study. In total, 15,976 subjects were
included in this study, divided into a Caucasian series (5769 PD
patients, 4988 controls) and an Asian series (1946 PD patients, 3273
controls). We selected 5 SNPs for the PARK16 locus (rs823139
[RAB7L1], rs708725 [RAB7L1], rs823156 [SLC41A1], rs11240572
[PM20D1], and rs708723 [RAB7L1]) because previously published
studies suggested associations with PD risk and the respective sites
also provided coverage of the PARK16 locus. We selected 2 SNPs
from the LRRK2 gene (rs1491942, rs7133914) due to previously
demonstrated associations with PD and minor allele frequencies
high enough to allow for reasonable interaction analysis. Analysis
was performed separately for the Caucasian series, the Asian series,and the combined series. We evaluated single variant associations
using ﬁxed effects logistic regression models adjusted for GEoPD
site. Pairwise multiplicative interactions between LRRK2 and
PARK16 variants were also examined using ﬁxed effects logistic
regression models. In addition to including terms for the given 2
individual variants and their interaction, these models were
adjusted for the individual GEoPD site. Odds ratios (ORs) and 95%
conﬁdence intervals (CIs) were estimated. Subjects were coded as
either 0 (absence of the minor allele) or 1 (presence of the minor
allele) for each variant. Variants with a MAF of 10% or greater in
both the Asian and Caucasian series were examined under an
additive model, with the subject coded as (0,1,2), depending on the
number of copies of the minor allele. To account for the 10 tests of
LRRK2-PARK16 interaction that were performed in each series
(Caucasian, Asian, or combined), we utilized a Bonferroni correction
for multiple testing separately in each series, after which 2-sided
p-values of 0.005 or lower were considered as statistically signiﬁ-
cant. All statistical analyses were performed using R Statistical
Software. The local Ethics Committee at each GEoPD site approved
the study. All participants signed an informed consent.3. Results
Of the 10 interactions that were examined between the PARK16
and LRRK2 variants, nonsigniﬁcant evidence of geneegene interac-
tionwas observed between LRRK2 rs1491942 and PARK16 rs11240572
in the combined series (interaction OR: 0.97, 95% CI: 0.74e1.01, p ¼
0.07, Supplementary Table 1). PARK16 rs11240572 appeared to have
no effect on PD risk for individualswith the commonGGgenotype for
LRRK2 rs1491942, but a slight protective effect for those with GC and
CC LRRK2 rs1491942 genotypes (see Supplementary Information).
Investigating this further in the stratiﬁed data (Supplementary
Table 6), we observed for noncarriers of PARK16 rs11240572, LRRK2
rs1491942 a statistically signiﬁcant higher risk of PD development in
the Caucasian and combined series (OR 1.17 and 1.15, p-value
<0.001). However, after correcting for multiple testing, it no longer
approached statistical signiﬁcance under the interaction model.
There were no other noteworthy interactions between LRRK2
rs1491942 and PARK16 variants in any series (all interaction p 0.25,
Supplementary Tables 3e5), or between LRRK2 rs7133914 and
PARK16 variants in the Caucasian series (all interaction p  0.096,
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1.20, which supports the lack of a biologically meaningful interaction
by lack of a notable deviation from an OR of 1. Between-site hetero-
geneity in interaction effects was generally relatively low (ranges
between 0% and 35% with most around 0%), lending consistency to
the lack of interaction. Models adjusted for age and gender using the
subset of subjects with complete information and random effects
models also produced similar results in geneegene interaction
analyses.
4. Discussion
The identiﬁcation of genetic mutations in genes linked to fa-
milial forms of PD (e.g., LRRK2, VPS35, and DNAJC13), and genetic
variability within the PARK16 locus in genome wide association
studies strongly implicates the role of retromer and lysosomal
pathway in PD pathogenesis (Heckman et al., 2014; Soto-Ortolaza
et al., 2013). Therefore, to understand the impact of interaction in
world-wide populations, we performed a largemulticenter study to
assess the genetic evidence of interaction between LRRK2 and
PARK16 locus. The results of our study do not provide evidence of a
genetic interaction between PARK16 and LRRK2 variants with regard
to risk of PD. Of note, the directionality of effect estimates, albeit
with a much weaker effect size observed in the present study,
involving the speciﬁc LRRK2 rs1491942/PARK16 rs11240572 inter-
action, are in agreement with previously published ﬁndings. Ge-
netic interaction studies are limited by sample size and power
because the variable of focus in an interaction study is the presence
of the genotype of interest for both variants, and this occurs much
less frequently than in the individual variant genotypes.
Therefore, even with our large sample size, power is still limited
to detect moderate to small geneegene interaction effects.
Although there was some degree of concordance between our
interaction ﬁndings and those that were previously reported, our
results were much weaker than the strong LRRK2-PARK16 interac-
tion that was previously reported (Beilina et al., 2014; MacLeod
et al., 2013). Even with the large GEoPD sample size, which we
have accrued to perform the present study, we are likely under-
powered to detect weaker interaction effects. In addition, lack of
genetic interaction does not exclude the presence of cellular or
functional interaction. However, such genetic studies will be critical
if we are to understand the role of geneegene interaction in disease
susceptibility.
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